AngioDynamics (NASDAQ:ANGO) Stock Price Passes Above 200 Day Moving Average - Here's What Happened

Key Points

• AngioDynamics shares surpassed their 200-day moving average during trading, reaching a high of $10.62 and last trading at $10.48.
• Multiple analysts have issued buy ratings for AngioDynamics, with price targets ranging from $16.00 to $24.00, alongside a consensus target price of $19.00.
• The company reported better-than-expected earnings with $80.16 million in revenue for the last quarter, surpassing forecasts, while also highlighting a negative net margin of 11.62% and a forecast for EPS between -0.350 to -0.250 for FY 2026.

AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $9.60 and traded as high as $10.62. AngioDynamics shares last traded at $10.48, with a volume of 501,981 shares changing hands.

Analyst Upgrades and Downgrades

ANGO has been the subject of a number of analyst reports. Lake Street Capital initiated coverage on AngioDynamics in a research report on Wednesday, July 16th. They set a "buy" rating and a $24.00 price objective for the company. Canaccord Genuity Group boosted their price target on AngioDynamics from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 16th. HC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of AngioDynamics in a research report on Wednesday, July 16th. Finally, Wall Street Zen upgraded AngioDynamics from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $19.00.

AngioDynamics Stock Down 2.2%

The business has a 50-day moving average price of $9.54 and a 200-day moving average price of $9.64. The company has a market capitalization of $437.59 million, a price-to-earnings ratio of -12.98 and a beta of 0.64.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.09. The company had revenue of $80.16 million for the quarter, compared to analyst estimates of $74.26 million. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%.AngioDynamics's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.06) earnings per share. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. As a group, sell-side analysts predict that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ANGO. State of Wyoming acquired a new position in AngioDynamics during the second quarter valued at $31,000. Tower Research Capital LLC TRC increased its position in AngioDynamics by 359.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier's stock worth $54,000 after purchasing an additional 4,268 shares during the last quarter. Raymond James Financial Inc. acquired a new position in AngioDynamics in the 2nd quarter worth about $90,000. ProShare Advisors LLC acquired a new position in AngioDynamics in the 4th quarter worth about $100,000. Finally, Cerity Partners LLC increased its position in AngioDynamics by 22.0% in the 1st quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock worth $121,000 after purchasing an additional 2,333 shares during the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.